120 related articles for article (PubMed ID: 37066337)
1. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients, as a function of therapeutic transfusion and hydroxyurea treatment.
D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Espinosa JM; Gordeuk VR; Gladwin MT
bioRxiv; 2023 Apr; ():. PubMed ID: 37066337
[TBL] [Abstract][Full Text] [Related]
2. Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.
D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Espinosa JM; Gordeuk VR; Gladwin MT
Haematologica; 2023 Dec; 108(12):3418-3432. PubMed ID: 37439373
[TBL] [Abstract][Full Text] [Related]
3.
D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Gordeuk VR; Gladwin MT
bioRxiv; 2023 Feb; ():. PubMed ID: 36824724
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Gordeuk VR; Gladwin MT
Am J Hematol; 2023 Jul; 98(7):1017-1028. PubMed ID: 36971592
[TBL] [Abstract][Full Text] [Related]
5. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
Drawz P; Ayyappan S; Nouraie M; Saraf S; Gordeuk V; Hostetter T; Gladwin MT; Little J
Clin J Am Soc Nephrol; 2016 Feb; 11(2):207-15. PubMed ID: 26672090
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE; Nevitt SJ
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
[TBL] [Abstract][Full Text] [Related]
7. Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates.
Yates AM; Joshi VM; Aygun B; Moen J; Smeltzer MP; Govindaswamy D; Dowdy J; Cotton A; Kang G; Ware RE; Hankins JS
Pediatr Blood Cancer; 2019 Jul; 66(7):e27717. PubMed ID: 30907497
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
9. Metabolic correlates to critical speed in murine models of sickle cell disease.
Cendali FI; Nemkov T; Lisk C; Lacroix IS; Nouraie SM; Zhang Y; Gordeuk VR; Buehler PW; Irwin D; D'Alessandro A
Front Physiol; 2023; 14():1151268. PubMed ID: 37007990
[No Abstract] [Full Text] [Related]
10. Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa.
Dubert M; Elion J; Tolo A; Diallo DA; Diop S; Diagne I; Sanogo I; Belinga S; Guifo O; Wamba G; Ngo Sack F; Boidy K; Kamara I; Traore Y; Diakite CO; Gbonon V; Faye BF; Seck M; Deme Ly I; Chelo D; N'Guetta R; Diop IB; Gaye B; Jouven X; Ranque B
Blood; 2017 Nov; 130(20):2215-2223. PubMed ID: 28931524
[TBL] [Abstract][Full Text] [Related]
11. Plasma Levels of Acyl-Carnitines and Carboxylic Acids Correlate With Cardiovascular and Kidney Function in Subjects With Sickle Cell Trait.
Nemkov T; Skinner S; Diaw M; Diop S; Samb A; Connes P; D'Alessandro A
Front Physiol; 2022; 13():916197. PubMed ID: 35910560
[TBL] [Abstract][Full Text] [Related]
12. Hyperkalemia and Metabolic Acidosis Occur at a Higher eGFR in Sickle Cell Disease.
Saraf SL; Derebail VK; Zhang X; Machado RF; Gordeuk VR; Lash JP; Little J
Kidney360; 2022 Apr; 3(4):608-614. PubMed ID: 35721605
[TBL] [Abstract][Full Text] [Related]
13. Red blood cells microparticles are associated with hemolysis markers and may contribute to clinical events among sickle cell disease patients.
Olatunya OS; Lanaro C; Longhini AL; Penteado CFF; Fertrin KY; Adekile A; Saad STO; Costa FF
Ann Hematol; 2019 Nov; 98(11):2507-2521. PubMed ID: 31493004
[TBL] [Abstract][Full Text] [Related]
14. Effects of red blood cell (RBC) transfusion on sickle cell disease recipient plasma and RBC metabolism.
Culp-Hill R; Srinivasan AJ; Gehrke S; Kamyszek R; Ansari A; Shah N; Welsby I; D'Alessandro A
Transfusion; 2018 Dec; 58(12):2797-2806. PubMed ID: 30265764
[TBL] [Abstract][Full Text] [Related]
15. Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.
Derebail VK; Ciccone EJ; Zhou Q; Kilgore RR; Cai J; Ataga KI
Am J Kidney Dis; 2019 Jul; 74(1):47-55. PubMed ID: 30797615
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
17. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
18. A cautionary note regarding hydroxyurea in sickle cell disease.
Vichinsky EP; Lubin BH
Blood; 1994 Feb; 83(4):1124-8. PubMed ID: 7509209
[TBL] [Abstract][Full Text] [Related]
19. Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications.
Tantawy AA; Adly AA; Ismail EA; Habeeb NM; Farouk A
Platelets; 2013; 24(8):605-14. PubMed ID: 23249216
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine levels in children with sickle cell disease and its correlation to tricuspid regurgitant jet velocity.
El-Shanshory M; Badraia I; Donia A; Abd El-Hameed F; Mabrouk M
Eur J Haematol; 2013 Jul; 91(1):55-61. PubMed ID: 23551575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
